Company

Strongbridge Biopharma plc

Headquarters: Trevose, PA, United States

Employees: 71

NASDAQ: SBBP

Market Cap

$135.7 Million

USD as of Oct. 1, 2021

Market Cap History

Strongbridge Biopharma plc market capitalization over time

Evolution of Strongbridge Biopharma plc market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Strongbridge Biopharma plc

Detailed Description

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company offers Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trials that for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.

Top 1-year algo backtest: +284.14%

$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Strongbridge Biopharma plc has the following listings and related stock indices.


Stock: NASDAQ: SBBP wb_incandescent

Stock: FSX: 69BN wb_incandescent

Details

Headquarters:

900 Northbrook Drive

Suite 200

Trevose, PA 19053

United States

Phone: 610 254 9200